Prognostic Value of Single Nodal Zone Metastasis in Non-Small-Cell Lung Cancer—A Multi-Institutional Study DOI Open Access

Samanta Nicosia,

Paraskevas Lybéris,

Stefano Rudella

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(9), P. 2938 - 2938

Published: April 24, 2025

Objectives: Lung cancer is the leading cause of cancer-related deaths worldwide and mediastinal lymph node involvement an important negative prognostic factor. Nevertheless, a single nodal zone has been reported to have favorable outcomes. This study aims assess whether prognosis non-small-cell lung (NSCLC) with single-zone varies by affected zone. Methods: We retrospectively analyzed patients NSCLC who underwent anatomical resection. The was statistically compared based on different zones. Results: A total 135 were enrolled. All resection systematic dissection. Lymph observed in 50 cases (37%) for upper zone, 36 (27%) aorto-pulmonary (AP) 41 (30%) subcarinal 8 (6%) lower median follow-up 37 months [ranging from 1 115 months]. Cancer recurrence 64 (52%) during this period. 2-year 4-year overall survival (OS) 69% 49%, respectively. relapse-free (RFS) 55% 41%. OS RFS change relating involved zones (p < 0.01). Lower predicts worse prognosis, better outcomes, AP intermediate survival. Conclusions: location nodes appears be factor NSCLC, significant impacts both RFS. It may play key role disease progression patient providing more personalized therapy.

Language: Английский

Use of lung-cancer trends for global and public health priorities DOI
Eunji Choi, Julie A. Barta

The Lancet Respiratory Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Transcriptome-based insights into the role of cancer-associated fibroblasts in lung adenocarcinoma prognosis and therapy DOI
Yinhe Feng, Jianming Zeng, Xiaoli Zhong

et al.

Computer Methods in Biomechanics & Biomedical Engineering, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 16

Published: March 12, 2025

Cancer-associated fibroblasts (CAFs) are related to drug resistance and prognosis of tumor patients. This study aimed investigate the relationship between treatment response in patients with CAF lung adenocarcinoma (LUAD). The data pertaining LUAD were obtained from Cancer Genome Atlas-LUAD GSE68465 datasets. Four different algorithms used quantify infiltration stromal scores. Weighted gene network co-expression analysis was identify CAF-related modules hub genes. Univariate Cox regression analysis, least absolute shrinkage selection operator multivariate construct signatures, whose ability predict verified by individual signature eight genes constructed, score calculated. high scores significantly worse than that low an independent risk factor for prognosis. Patients sensitive some chemotherapy drugs, most cases, they non-responsive immunotherapy. Eight-gene may patient evaluate clinical responses immunotherapy, enabling individualized

Language: Английский

Citations

0
Development of indole hybrids for potential lung cancer treatment-part I: nitrogen-containing six-membered aromatic heterocycles DOI

Shijia Zhao,

Zhi Xu

Future Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 17

Published: March 29, 2025

Lung cancer is the most prevalent invasive malignancy and leading cause of cancer-related death. Chemotherapy vital for lung therapy, but multidrug resistance responsible majority fatalities, creating an imperative demand to develop novel chemotherapeutics. Indole a valuable anti-lung pharmacophore since its derivatives could act on cells through various mechanisms. Notably, indole hybrids inhibit multiple targets simultaneously have potential overcome shortcomings traditional Moreover, many such as indole-pyrimidine hybrid osimertinib indole-hydroxamic acid panobinostat, are either under clinical evaluations or already been approved therapy. This indicates that rational design represents highly prospective approach development new chemotherapeutic agents. review focuses exploring therapeutic delves into their action mechanisms well structure-activity correlations, covering articles published between 2021 present. The ultimate goal offer foundation in future.

Language: Английский

Citations

0
Development of indole hybrids for potential lung cancer treatment - part II DOI
Shanshan Huang,

Zhi Xu,

Yafei Zhuang

et al.

Future Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 17

Published: March 30, 2025

Lung cancer has become the most prevalent for past three decades, and 5-years survival rate of lung is only ~20% nowadays. Chemotherapy mainstay therapy, especially non-small cell cancer. However, drug resistance represents a principal cause therapeutic failure in leading to insensitivity, tumor recurrence, disease progression. Indole hybrids have potential conquer resistance, enhance efficacy, reduce adverse events, improve pharmacokinetic properties due their capacity inhibit multiple targets simultaneously. Moreover, indole osimertinib, mobocertinib, cediranib, vizimpro are currently applied clinics demonstrating that valuable scaffolds treatment eradication This review provides comprehensive overview evolving landscape with vitro vivo efficacy against cancer, structure–activity relationships as well mechanisms action also discussed, covering articles published from 2021 onward.

Language: Английский

Citations

0
The rising influence of lipid metabolism in lung cancer: a global research perspective DOI Creative Commons
Chaoqun Wang, Ming Lei, Wei Wang

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: March 31, 2025

Lung cancer is a prevalent malignant neoplasm globally and the leading cause of cancer-related mortality, posing significant threat to human health imposing considerable societal burden. Researchers have recently focused more on lipid metabolism in lung cancer. However, date, there has been no bibliometric analysis relation metabolism. This study used methods analyze link between Publications from 1995 2024 were sourced Web Science Core Collection (WoSCC). The Microsoft Excel, R-bibliometrix, CiteSpace, VOSviewer software visualize data. In this study, total 535 publications identified, with marked increase number observed post-2016. Both China United States exerted substantial influence domain. Notably, Chinese Academy Sciences Huazhong University Technology demonstrated leadership various aspects research related Professor Ana Ramirez de Molina Frontiers Oncology most productive authors journals respectively. Besides, keywords like "lipid metabolism", "lung cancer", "expression", "metabolism" "growth" central current are expected continue driving future trends studies. Research relationship was still its early stages. Targeting represented promising therapeutic strategy, as inhibiting key enzymes involved biosynthesis uptake potential impede progression mitigate drug resistance. first thoroughly summarize developments area over past thirty years, providing scholars updated insights identifying directions.

Language: Английский

Citations

0
Prognostic Value of Single Nodal Zone Metastasis in Non-Small-Cell Lung Cancer—A Multi-Institutional Study DOI Open Access

Samanta Nicosia,

Paraskevas Lybéris,

Stefano Rudella

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(9), P. 2938 - 2938

Published: April 24, 2025

Objectives: Lung cancer is the leading cause of cancer-related deaths worldwide and mediastinal lymph node involvement an important negative prognostic factor. Nevertheless, a single nodal zone has been reported to have favorable outcomes. This study aims assess whether prognosis non-small-cell lung (NSCLC) with single-zone varies by affected zone. Methods: We retrospectively analyzed patients NSCLC who underwent anatomical resection. The was statistically compared based on different zones. Results: A total 135 were enrolled. All resection systematic dissection. Lymph observed in 50 cases (37%) for upper zone, 36 (27%) aorto-pulmonary (AP) 41 (30%) subcarinal 8 (6%) lower median follow-up 37 months [ranging from 1 115 months]. Cancer recurrence 64 (52%) during this period. 2-year 4-year overall survival (OS) 69% 49%, respectively. relapse-free (RFS) 55% 41%. OS RFS change relating involved zones (p < 0.01). Lower predicts worse prognosis, better outcomes, AP intermediate survival. Conclusions: location nodes appears be factor NSCLC, significant impacts both RFS. It may play key role disease progression patient providing more personalized therapy.

Language: Английский

Citations

0